Dr Aigner is a biologist with a PhD in medical microbiology from University Hospital Regensburg. Since joining University Hospital Erlangen in 2008, he has focused on adoptive T-cell therapy, led clinical trials of antigen- and multivirus-specific T cells, and established one of Germany’s first academic GMP laboratories for CAR T-cell manufacturing. His teams have produced CAR T and TRUCK cell therapies for more than 100 patients across cancer and autoimmune indications, including first-in-world treatments for systemic lupus erythematosus. Dr. Aigner serves on the medical faculty in Erlangen and participates in national and international cell and gene therapy organizations, including EBMT, ISCT, and the Bavarian Cancer Research Center’s GMP group.